DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for sinoatrial node disorder — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSinoatrial node disorder maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sinoatrial node disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
A-kinase anchoring protein 13 (AKAP13) — AKAP13 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4D0N · 2.1 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Sinoatrial node disorder, also called sinus node dysfunction, is most commonly a disease of the elderly, driven by degenerative fibrosis and other age-dependent changes. Current treatment is limited to pacemaker implantation, which carries substantial medical costs and complications. A 2022 review notes that emerging evidence has identified various genetic abnormalities that can cause the disorder, and that understanding these molecular mechanisms is hoped to point toward novel therapeutic targets, but no drug therapy is described in that review.
A 1968 description of the sick sinus syndrome lists its clinical features: persistent severe unexpected sinus bradycardia, short intervals of sinus rhythm cessation with other rhythms supervening, long periods of sinus arrest without rescue rhythm producing cardiac arrest, untreated chronic atrial fibrillation with slow ventricular rate, no sinus rhythm after cardioversion, and SA exit block. Symptoms arise from hypoperfusion of vital organs. No drug treatment is mentioned in that paper either.
A 2021 case report describes a patient with bicuspid aortic valve and sinoatrial node dysfunction whose junctional escape beat could accelerate with physiological needs and provided for normal daily life. The authors suggest this observation could be potentially significant for identifying causes and choosing treatment strategies using ECG monitoring, but they do not report testing any drug or intervention. The report offers no data on survival or response rates.
What is still missing is any clinical trial testing a drug for sinoatrial node disorder, any validated molecular target that has led to a candidate therapy in patients, and any patient stratification beyond the broad category of age-related degenerative disease. Funding for preclinical drug development and for trials that might repurpose existing compounds remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Physiology-Heart and Circulatory Physiology · 2022 · 44 citations · open access
Sinus node dysfunction: current understanding and future directions
AbstractThe sinoatrial node (SAN) is the primary pacemaker of the heart. Normal SAN function is crucial in maintaining proper cardiac rhythm and contraction. Sinus node dysfunction (SND) is due to abnormalities within the SAN, which can affect the heartbeat frequency, regularity, and the propagation of electrical pulses through the cardiac conduction system. As a result, SND often increases the risk of cardiac arrhythmias. SND is most commonly seen as a disease of the elderly given the role of degenerative fibrosis as well as other age-dependent changes in its pathogenesis. Despite the prevalence of SND, current treatment is limited to pacemaker implantation, which is associated with substantial medical costs and complications. Emerging evidence has identified various genetic abnormalities that can cause SND, shedding light on the molecular underpinnings of SND. Identification of these molecular mechanisms and pathways implicated in the pathogenesis of SND is hoped to identify novel therapeutic targets for the development of more effective therapies for this disease. In this review article, we examine the anatomy of the SAN and the pathophysiology and epidemiology of SND. We then discuss in detail the most common genetic mutations correlated with SND and provide our perspectives on future research and therapeutic opportunities in this field.
AbstractAlthough little basic information exists regarding atrial disease, certain clinical states can be grouped into a syndrome resulting from a failing sinoatrial (SA) node. One or more of the following symptoms appears: persistent, severe, and unexpected sinus bradycardia; cessation of sinus rhythm for short intervals with other rhythms supervening; long periods of sinus arrest without rescue rhythm, which produces cardiac arrest; untreated chronic atrial fibrillation with slow ventricular rate; no sinus rhythm after cardioversion; SA exit block. Symptoms spring from hypoperfusion of vital organs.
Cardiovascular Innovations and Applications · 2021 · 0 citations · open access
Junctional Pacemaker May Replace the Sinoatrial Node
AbstractJunctional rhythm is usually seen in the clinic with different causes. We report a case of bicuspid aortic valve accompanied by sinoatrial node dysfunction. The junctional escape beat could accelerate with physiological needs and provided for the normal needs of daily life when dysfunction of the sinoatrial node occurred, which provides a new way for the treatment of sinoatrial node dysfunction. Our findings could be potentially significant for identifying causes and choosing appropriate treatment strategies by using ECG monitoring in the clinic in the future.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
